Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.78 -0.7%	$0.71	$0.51 ▼ $1.38	$75.07M	0.28	324,997 shs	77,414 shs
DARE Dare Bioscience	$2.05 -1.7%	$2.43	$1.83 ▼ $9.19	$27.49M	1.11	611,172 shs	91,684 shs
IGMS IGM Biosciences	$1.27	$1.27	$0.92 ▼ $22.50	$76.57M	0.6	480,746 shs	N/A
OTLK Oncobiologics	$2.74 -7.9%	$2.04	$0.87 ▼ $8.32	$121.84M	0.26	890,268 shs	6.26 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	-0.01%	-3.00%	+6.18%	+15.54%	-38.62%
DARE Dare Bioscience	-1.89%	-1.42%	-19.07%	-25.71%	-41.41%
IGMS IGM Biosciences	0.00%	0.00%	0.00%	+4.10%	-87.85%
OTLK Oncobiologics	+10.82%	+7.22%	+45.59%	+84.47%	-60.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	1.9995 of 5 stars	3.5	2.0	0.0	0.6	0.8	1.3
DARE Dare Bioscience	2.4981 of 5 stars	3.5	5.0	0.0	2.6	0.0	0.0
IGMS IGM Biosciences	4.2606 of 5 stars	3.0	3.0	4.6	1.1	3.3	1.3
OTLK Oncobiologics	2.3124 of 5 stars	3.4	2.0	0.0	4.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.38	204.49% Upside
DARE Dare Bioscience	3.00	Buy	$12.00	486.80% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	333.07% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	251.01% Upside

Current Analyst Ratings Breakdown

Latest DARE, OTLK, ASRT, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	OTLK Oncobiologics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.60	$0.05 per share	16.01	$1.27 per share	0.61
DARE Dare Bioscience	$10K	2,756.66	N/A	N/A	($0.69) per share	-2.96
IGMS IGM Biosciences	$145.05M	0.53	N/A	N/A	$1.67 per share	0.76
OTLK Oncobiologics	$1.51M	80.71	N/A	N/A	($3.09) per share	-0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	26.00	N/A	-36.97%	-38.19%	-15.45%	11/10/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	11/13/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	11/14/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.57	N/A	N/A	N/A	N/A	N/A	-332.30%	N/A

Latest DARE, OTLK, ASRT, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/14/2025	Q3 2025	OTLK Oncobiologics	-$0.42	-$0.44	-$0.02	-$0.55	$1.66 million	$1.51 million
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.34
DARE Dare Bioscience	N/A	0.34	0.34
IGMS IGM Biosciences	N/A	17.66	17.66
OTLK Oncobiologics	N/A	0.67	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
DARE Dare Bioscience	6.70%
IGMS IGM Biosciences	42.79%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
DARE Dare Bioscience	4.80%
IGMS IGM Biosciences	57.00%
OTLK Oncobiologics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
DARE Dare Bioscience	30	13.48 million	12.83 million	Not Optionable
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
OTLK Oncobiologics	20	44.42 million	42.29 million	Optionable

DARE, OTLK, ASRT, and IGMS Headlines

Recent News About These Companies

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

August 24 at 10:02 AM | seekingalpha.com

Oncobiologics FY2025 EPS Forecast Raised by HC Wainwright

August 22, 2025 | marketbeat.com

Oncobiologics FY2025 EPS Estimate Increased by HC Wainwright

August 22, 2025 | americanbankingnews.com

Oncobiologics (NASDAQ:OTLK) Releases Earnings Results, Misses Estimates By $0.02 EPS

August 18, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Earns Neutral Rating from Chardan Capital

August 17, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan Capital

August 17, 2025 | americanbankingnews.com

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

August 14, 2025 | zacks.com

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

August 14, 2025 | globenewswire.com

Oncobiologics (OTLK) Projected to Post Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 5, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Trading Down 1.5% - Should You Sell?

August 3, 2025 | marketbeat.com

New Strong Buy Stocks for July 30th

July 30, 2025 | zacks.com

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

July 24, 2025 | globenewswire.com

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

OTLK Outlook Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

July 1, 2025 | globenewswire.com

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

June 18, 2025 | globenewswire.com

Microsoft shares temp fix for Outlook crashes when opening emails

June 17, 2025 | bleepingcomputer.comB

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, OTLK, ASRT, and IGMS Company Descriptions

Assertio NASDAQ:ASRT

$0.78 -0.01 (-0.73%)

As of 03:25 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Dare Bioscience NASDAQ:DARE

$2.04 -0.04 (-1.68%)

As of 03:27 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)

As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Oncobiologics NASDAQ:OTLK

$2.74 -0.24 (-7.91%)

As of 03:28 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time